265 related articles for article (PubMed ID: 36297404)
1. [
Hennrich U; Eder M
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297404
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
[TBL] [Abstract][Full Text] [Related]
3. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
4. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Liu X; Fang GC; Lu H; Shi ZD; Chen ZS; Han CH
Drugs Today (Barc); 2023 Jan; 59(1):37-49. PubMed ID: 36811416
[TBL] [Abstract][Full Text] [Related]
5. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
6. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
7. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Shah H; Ravi P; Sonpavde G; Jacene H
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1163-1175. PubMed ID: 36305305
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
9. Update on radioligand therapy with
Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting biochemical response and survival benefits following radioligand therapy with [
Manafi-Farid R; Harsini S; Saidi B; Ahmadzadehfar H; Herrmann K; Briganti A; Walz J; Beheshti M
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4028-4041. PubMed ID: 33677734
[TBL] [Abstract][Full Text] [Related]
11. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
12. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer.
Kostos L; Buteau JP; Hofman MS; Azad AA
Ther Adv Med Oncol; 2023; 15():17588359231179309. PubMed ID: 37323184
[TBL] [Abstract][Full Text] [Related]
13.
Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
Front Oncol; 2022; 12():835956. PubMed ID: 35402274
[TBL] [Abstract][Full Text] [Related]
14. Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management.
Mahajan S; Grewal RK; Friedman KP; Schöder H; Pandit-Taskar N
Transl Oncol; 2022 Jul; 21():101445. PubMed ID: 35523007
[TBL] [Abstract][Full Text] [Related]
15. RadioLigand Therapy with [
Terroir M; Lamesa C; Krim M; Vija L; Texier JS; Cassou-Mounat T; Delord JP; Vallot D; Courbon F
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242537
[TBL] [Abstract][Full Text] [Related]
16. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
17. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
18. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
19. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
20. Matched-pair analysis of [
Hartrampf PE; Weinzierl FX; Buck AK; Rowe SP; Higuchi T; Seitz AK; Kübler H; Schirbel A; Essler M; Bundschuh RA; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3269-3276. PubMed ID: 35243517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
